Virologic and immunologic activity of PegIntron in HIV disease

Jonathan B. Angel, Wayne Greaves, Jianmin Long, Douglas Ward, Allan E Rodriguez, Daniele Scevola, Edwin Dejesus

Research output: Contribution to journalArticle

4 Citations (Scopus)


OBJECTIVE: The primary objectives of this study were to evaluate the safety, tolerability, and antiviral activity of pegylated interferon-α (PegIntron) in HIV-1 treatment-experienced patients failing their current antiretroviral regimen. DESIGN: This was a phase II, multicenter, randomized, double-blind, placebo-controlled study. METHODS: Patients were randomized to receive either weekly subcutaneous PegIntron 0.5, 1.0, 1.5, or 3 μg/kg or placebo added to their failing antiretroviral regimen for the first 4 weeks of study. Individuals who achieved more than 0.5 log10 reduction in HIV RNA at week 4 were allowed to continue study medication with optimization of their antiretroviral therapy for an additional 24 weeks. RESULTS: In the 259 patients included in the intent-to-treat analysis, changes in plasma HIV RNA from baseline to week 4 were-0.25 (P > 0.5),-0.46 (P = 0.024),-0.39 (P = 0.008),-0.53 (P < 0.001), and-0.17 (P > 0.5) log10 copies/ml in the 0.5, 1.0, 1.5, and 3.0 μg/kg and placebo arms, respectively. No significant changes were seen in CD4 T-cell parameters in any of the treatment or control arms. Adverse events (most commonly fever, flu-like symptoms, other constitutional symptoms, and psychiatric symptoms) resulted in discontinuation of study medication in 13, 17, 16, 28, and 2% of patients in the 0.5, 1.0, 1.5, 3.0 μg/kg, and placebo group, respectively. CONCLUSION: The demonstration of significant antiviral activity in a heavily pretreated patient population with acceptable toxicity and only weekly dosing makes PegIntron a potentially valuable therapy for patients with HIV infection that warrants further investigation in a broader population of patients.

Original languageEnglish
Pages (from-to)2431-2438
Number of pages8
Issue number18
StatePublished - Nov 1 2009


Antiviral Agents
HIV Infections


  • Antiretroviral therapy
  • Interferon
  • PegIntron

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Angel, J. B., Greaves, W., Long, J., Ward, D., Rodriguez, A. E., Scevola, D., & Dejesus, E. (2009). Virologic and immunologic activity of PegIntron in HIV disease. AIDS, 23(18), 2431-2438.

Virologic and immunologic activity of PegIntron in HIV disease. / Angel, Jonathan B.; Greaves, Wayne; Long, Jianmin; Ward, Douglas; Rodriguez, Allan E; Scevola, Daniele; Dejesus, Edwin.

In: AIDS, Vol. 23, No. 18, 01.11.2009, p. 2431-2438.

Research output: Contribution to journalArticle

Angel, JB, Greaves, W, Long, J, Ward, D, Rodriguez, AE, Scevola, D & Dejesus, E 2009, 'Virologic and immunologic activity of PegIntron in HIV disease', AIDS, vol. 23, no. 18, pp. 2431-2438.
Angel JB, Greaves W, Long J, Ward D, Rodriguez AE, Scevola D et al. Virologic and immunologic activity of PegIntron in HIV disease. AIDS. 2009 Nov 1;23(18):2431-2438.
Angel, Jonathan B. ; Greaves, Wayne ; Long, Jianmin ; Ward, Douglas ; Rodriguez, Allan E ; Scevola, Daniele ; Dejesus, Edwin. / Virologic and immunologic activity of PegIntron in HIV disease. In: AIDS. 2009 ; Vol. 23, No. 18. pp. 2431-2438.
title = "Virologic and immunologic activity of PegIntron in HIV disease",
abstract = "Lippincott Williams & Wilkins.",
keywords = "Antiretroviral therapy, Interferon, PegIntron",
author = "Angel, {Jonathan B.} and Wayne Greaves and Jianmin Long and Douglas Ward and Rodriguez, {Allan E} and Daniele Scevola and Edwin Dejesus",
year = "2009",
month = "11",
day = "1",
doi = "10.1097/QAD.0b013e32832f30ca",
language = "English",
volume = "23",
pages = "2431--2438",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "18",



T1 - Virologic and immunologic activity of PegIntron in HIV disease

AU - Angel, Jonathan B.

AU - Greaves, Wayne

AU - Long, Jianmin

AU - Ward, Douglas

AU - Rodriguez, Allan E

AU - Scevola, Daniele

AU - Dejesus, Edwin

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - Antiretroviral therapy

KW - Interferon

KW - PegIntron

UR -

UR -

U2 - 10.1097/QAD.0b013e32832f30ca

DO - 10.1097/QAD.0b013e32832f30ca

M3 - Article

C2 - 19898218

AN - SCOPUS:72949099689

VL - 23

SP - 2431

EP - 2438



SN - 0269-9370

IS - 18

ER -